Allarity Therapeutics announces DRP licensing and lab services deal with EU biotech

Allarity Therapeutics, Inc.

Non-exclusive global license to selected DRP algorithms in breast cancer granted to an undisclosed EU-based biotech company.
Allarity will provide advanced transcriptome analysis services from its Denmark lab; purchase commitments secured for next year.
Company states the agreement is not expected to have a significant impact on its financial outlook.
CEO Thomas Jensen says deal validates DRP platform and offsets internal operating costs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.